Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/27/2022 -- Results Q3 2022 -- 1.75 --
10/27/2022 08:00 EST Earnings Call Q3 2022 -- -- --
07/28/2022 -- Results Q2 2022 1.87 1.71 9.57%
07/28/2022 08:00 EST Earnings Call Q2 2022 -- -- --
04/28/2022 -- Results Q1 2022 2.14 1.83 17.11%
04/28/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/03/2022 -- Results Q4 2021 1.80 1.52 18.08%
02/03/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/27/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/28/2022
Beat/Miss Upgrade
Return Since -0.94%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
URL https://www.merck.com
Investor Relations URL https://www.merck.com/investor-relations
HQ State/Province New Jersey
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Oct. 27, 2022
Last Earnings Release Jul. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Sep. 14, 2022

Dividends

Dividend Per Share (TTM) 2.72
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 2.126
Yield to Sector 1.692
Yield to Industry 0.8445
Last Dividend Amt. 0.69
Dividend Frequency Quarterly
Last Ex-Dividend Date Sep. 14, 2022
Yield (TTM) 3.15%
Forward Yield 3.12%
Payout Ratio 41.06%
Cash Payout Ratio 47.28%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) Yes

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
18.24%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.66%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
18.08%
--
--
--
--
28.09%
434.1%
143.1%
-50.54%
3.97%
-7.55%
22.25%
15.17%
27.62%
-2.00%
0.87%
6.48%
1.16%
15.32%
24.40%
-5.14%
16.21%
10.85%
11.45%
-1.59%
As of October 05, 2022.

Profile

Edit
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
URL https://www.merck.com
Investor Relations URL https://www.merck.com/investor-relations
HQ State/Province New Jersey
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Oct. 27, 2022
Last Earnings Release Jul. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Sep. 14, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
XLV 1.758B USD 4.70%
SCHD 1.561B USD 4.19%
VHCIX 732.89M USD 3.94%
VEIPX 1.262B USD 2.51%
GEQAX 721.35M USD 2.02%
MEIGX 967.34M USD 1.66%
VHYAX 917.34M USD 1.58%
VYM 917.34M USD 1.58%
VIVAX 1.889B USD 1.31%
VTV 1.889B USD 1.31%
IVV 1.951B USD 0.72%
SPY 2.436B USD 0.70%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter MRK Tweets